"Protagen has established an industrial standard for automated highthroughput expression of recombinant human proteins and their respective use for biomarker development and clinical validation. In addition, we have built an excellent and unique network of internationally renowned clinical partners in all relevant indication areas”, explains Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen. „The expertise of Kairos will complement our technology position. In addition, it will support our collaborations with drug development companies in a very efficient way and will allow for more effective project and study management.”
Martin Zünkeler, founder and General Manager of Kairos adds "Decisive for the partnership with Protagen was the high grade of automation established in the labs, and the overall high quality of the processes employed. For instance, the fully automated aliquotation with latest robotic systems is already daily routine at Protagen. By and large, this is an ideal situation to adapt and develop software solutions for study management and biobanking”.